+33 (0)251 252 000 contact@inflectisbioscience.com

Our Commitment

We’re a biotechnology company developing new treatments for people living with neurological diseases like Amyotrophic Lateral Sclerosis (ALS), Charcot-Marie-Tooth (CMT) and Multiple Sclerosis (MS).

Revolutionizing Neurological Disease Treatment: A Multifaceted Approach
Current therapeutic approaches for neurological diseases often fall short, providing only limited and transient symptomatic relief. The insidious loss of neuronal cells remains largely unmitigated, leaving patients grappling with progressive decline. These conditions, with their multifactorial origins, defy simplistic solutions.

Beyond the “One Gene, One Drug” Paradigm
Conventional drug discovery has long adhered to the “one gene, one drug, one disease” philosophy. However, in the intricate realm of neurodegeneration, this approach may not unlock the breakthroughs we urgently need. Neurodegenerative diseases, like ALS, but also Alzheimer and Parkinson diseases, arise from a complex interplay of genetic, environmental, and cellular factors. Singular interventions often miss the mark.

Polypharmacology: A New Frontier
Clinicians and scientists are increasingly drawn to a different path, one that embraces polypharmacology, an approach to pharmacological intervention that considers the complexity of disease state processes. This strategy involves simultaneously targeting multiple proteins implicated in disease development with one drug. By addressing diverse etiologies, polypharmacological treatments offer a more comprehensive impact. They tackle not just symptoms but also the multiple underlying mechanisms driving neurodegeneration.

InFlectis is developing a family of polypharmacological small molecules that are set apart from conventional therapies in the battle against neurological diseases.

Elif Ildem CMT

Elif Ildem is training for the Paralympics in Japan in 2021. Since she started swimming as part of rehabilitation related to CMT, she has won several medals and competitions.